Mallinckrodt PLC (MNKPF)

OTCMKTS: MNKPF · Delayed Price · USD
25.50
0.00 (0.00%)
Jun 27, 2022 12:00 AM EDT - Market closed
0.00%
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) -8.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close 25.50
Day's Range n/a
52-Week Range 0.10 - 31.00
Beta 2.72
Analysts n/a
Price Target n/a
Earnings Date n/a

About MNKPF

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gas... [Read more...]

Industry Drug Manufacturers-Specialty & Generic
Founded 1867
Employees 2,778
Stock Exchange OTCMKTS
Ticker Symbol MNKPF
Full Company Profile

News

Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Associ...

-Post-hoc analyses showcase Mallinckrodt's commitment to patients with HRS involving rapid reduction in kidney function, 1 an acute and life-threatening condition 2 - DUBLIN , June 23, 2022 /PRNewswire/...

Mallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial Flexibility

Appoints Sigurdur Olafsson as President and Chief Executive Officer DUBLIN, Ireland , June 16, 2022 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has success...

Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome

DUBLIN , June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the resubmission of the Company's New Drug Application (NDA) to the U.S. Foo...

Mallinckrodt Announces Anticipated Chapter 11 Emergence and Provides Update on Trading of New Ordinary Shares

DUBLIN , June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it expects to complete its reorganization process, emerge from Chapter 11 ...

High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement

Company Expects to Complete Irish Examinership and Emerge from Chapter 11 in the Next Few Weeks DUBLIN , April 27, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company"...

Mallinckrodt Announces Publication of Real-World Data from Retrospective Study on the Investigational Use of Inhaled ...

– Medical chart review study, published in Drugs in Context, evaluated the real-world use of INOmax® (nitric oxide) gas, for inhalation in hospitalized COVID-19 patients with mild-to-moderate acute resp...

Penny Stock Mallinckrodt Settles For $260 Million In DOJ Medicaid Suit

DOJ Settles For $260 million With Penny Stock Mallinckrodt The post Penny Stock Mallinckrodt Settles For $260 Million In DOJ Medicaid Suit appeared first on Penny Stocks to Buy, Picks, News and Informat...

Mallinckrodt Provides a Regulatory Update on Terlipressin

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Respon...

Mallinckrodt Plan of Reorganization Confirmed by U.S. Court

DUBLIN, Feb. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that its Plan of Reorganization (the "Plan") has been confirmed by the U.S. Bankr...

Mallinckrodt Earns Top Marks Again in Human Rights Campaign Foundation's 2022 Corporate Equality Index

DUBLIN, Jan. 31, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, announced that it received a score of 100 on the Human Rights Campaign Foundation's 2022 Corp...

Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogenei...

DUBLIN , Dec. 16, 2021 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced enrollment of the first patient in StrataSOMA, a Phase 1/2a clinical trial t...

Buxton Helmsley Publicly Responds to Departure of Mallinckrodt Plc. CCO, After Open Letter to U.S. SEC Detailing Acco...

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant ho...

Mallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients w...

DUBLIN, Nov. 12, 2021 /PRNewswire/ -- Mallinckrodt plc , (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced findings from two retrospective medical chart review studies on real world o...

Buxton Helmsley Publicly Responds to Resignation of Mallinckrodt Plc. SVP, Finance, Days After Open Letter to U.S. SE...

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant ho...

The Buxton Helmsley Group Calls on U.S. Securities and Exchange Commission to Intervene in Mallinckrodt Plc. Fraud In...

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant ho...

Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal ...

DUBLIN, Oct. 25, 2021 /PRNewswire/ --  Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results from a retrospective medical chart review study examining treatment ...

Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of U...

DUBLIN, Sept. 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached an agreement with the Official Committee of Opioid Related C...

Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns

DUBLIN, July 7, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced publication of results from the pivotal Phase 3 STRATA2016 clinical trial of S...

Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Soci...

DUBLIN, July 1, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European Respiratory Society...

Mallinckrodt Wins FDA Approval For Its Regenerative Skin Burn Graft

Following four months of regulatory delays amid the COVID-19 pandemic, the FDA has finally approved Mallinckrodt Plc's (OTC: MNKKQ) regenerative tissue graft for the treatment of second-degree burns. Th...

Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in...

DUBLIN, June 15, 2021 /PRNewswire/ --  Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (...

Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Ke...

DUBLIN, May 3, 2021 /PRNewswire/ --  Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to assess the efficacy a...

Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry ...

DUBLIN, April 30, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing the safety and e...

National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards

ST. LOUIS, March 29, 2021 /PRNewswire/ --  Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that its Specialty Generics division has been recognized as Manufacturin...

Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of...

DUBLIN, March 10, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached agreement with an ad hoc group of first lien term lenders h...